Browse > Article
http://dx.doi.org/10.3857/jkstro.2011.29.2.83

In Vitro Radiosensitization of Flavopiridol Did Not Translated into In Vivo Radiosensitization  

Kim, Su-Zy (Department of Radiation Oncology, The Catholic University of Korea School of Medicine)
Publication Information
Radiation Oncology Journal / v.29, no.2, 2011 , pp. 83-90 More about this Journal
Abstract
Purpose: Flavopiridol enhanced radiation-induced apoptosis of cancer cells in our previous in vitro study. The purpose of this study was to assess if flavopiridol could enhance the radioresponse of mouse mammary tumors in vivo. Materials and Methods: Balb/c mice bearing EMT-6 murine mammary carcinoma were treated with flavopiridol only, radiation only, or both for 7 days. Flavopiridol was administered 2.5 mg/kg twice a day intraperitoneally (IP). Radiation was delivered at a 4 Gy/fraction at 24-h intervals for a total dose of 28 Gy. Tumor volume was measured and compared among the different treatment groups to evaluate the in vivo radiosensitizing effect of flavopiridol. Tumors were removed from the mice 20 days after treatment, and TUNEL and Immunohistochemical stainings were performed. Results: Significant tumor growth delay was observed in the radiation only and combined treatment groups, when compared with the control group. However, there was no significant difference between the tumor growth curves of the control and flavopiridol only group or between the radiation only and combination treatment group. Apoptotic cells of different treatment groups were detected by terminal deoxynucleotidyl transferase-medicated nick end labeling (TUNEL) staining. The expressions of Ku70 in tumor tissues from the different groups were analyzed by immunohistochemistry. Similarly, no significant difference was found between the apoptotic rate or Ku70 expression among the different treatment groups. Conclusion: Flavopiridol did not show evidence of enhancing the radioresponse of mouse mammary tumors in this study.
Keywords
Flavopiridol; Radiation; Radiosensitization;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Willingham MC. Cytochemical methods for the detection of apoptosis. J Histochem Cytochem 1999;47:1101-1110   DOI   ScienceOn
2 Raju U, Nakata E, Mason KA, Ang KK, Milas L. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res 2003;63:3263-3267
3 Jung C, Motwani M, Kortmansky J, et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells. Clin Cancer Res 2003;9:6052-6061
4 Newcomb EW, Lymberis SC, Lukyanov Y, et al. Radiation sensitivity of GL261 murine glioma model and enhanced radiation response by flavopiridol. Cell Cycle 2006;5:93-99   DOI   ScienceOn
5 Kim S, Wu HG, Shin JH, Park HJ, Kim IA, Kim IH. Enhancement of radiation effects by flavopiridol in uterine cervix cancer cells. Cancer Res Treat 2005;37:191-195   DOI   ScienceOn
6 Kim S, Kwon EK, Lee SH, Park HJ, Wu HG. Effect of flavopiridol on radiation-induced apoptosis of human laryngeal and lung cancer cells. J Korean Soc Ther Radiol Oncol 2007;25:227-232
7 Jeggo PA. Identification of genes involved in repair of DNA double-strand breaks in mammalian cells. Radiat Res 1998;150(5 Suppl):S80-S91   DOI
8 Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000;92:376-387   DOI
9 Worland PJ, Kaur G, Stetler-Stevenson M, Sebers S, Sartor O, Sausville EA. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells: correlation with decreased H1 kinase activity. Biochem Pharmacol 1993;46:1831-1840   DOI   ScienceOn
10 Sedlacek HH. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 2001;38:139-170   DOI   ScienceOn
11 Patel V, Senderowicz AM, Pinto D Jr, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 1998;102:1674-1681   DOI   ScienceOn
12 Melillo G, Sausville EA, Cloud K, Lahusen T, Varesio L, Senderowicz AM. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 1999;59:5433-5437
13 Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 1997;57:3375-3380
14 Omori S, Takiguchi Y, Suda A, et al. Suppression of a DNA double-strand break repair gene, Ku70, increases radio-and chemosensitivity in a human lung carcinoma cell line. DNA Repair (Amst) 2002;1:299-310   DOI   ScienceOn
15 Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999;5:1876-1883
16 Senderowicz AM. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 1999;17:313-320   DOI   ScienceOn
17 Gu Y, Jin S, Gao Y, Weaver DT, Alt FW. Ku70-deficient embryonic stem cells have increased ionizing radiosensitivity, defective DNA end-binding activity, and inability to support V(D)J recombination. Proc Natl Acad Sci USA 1997;94:8076-8081   DOI   ScienceOn
18 Ouyang H, Nussenzweig A, Kurimasa A, et al. Ku70 is required for DNA repair but not for T cell antigen receptor gene recombination in vivo. J Exp Med 1997;186:921-929   DOI   ScienceOn
19 Camphausen K, Brady KJ, Burgan WE, et al. Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci. Mol Cancer Ther 2004;3:409-416
20 Hara T, Omura-Minamisawa M, Kang Y, Cheng C, Inoue T. Flavopiridol potentiates the cytotoxic effects of radiation in radioresistant tumor cells in which p53 is mutated or Bcl-2 is overexpressed. Int J Radiat Oncol Biol Phys 2008;71:1485-1495   DOI   ScienceOn
21 Mason KA, Hunter NR, Raju U, et al. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse. Int J Radiat Oncol Biol Phys 2004;59:1181-1189   DOI   ScienceOn
22 MacLachlan TK, Sang N, Giordano A. Cyclins, cyclindependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995;5:127-156   DOI   ScienceOn
23 Patel V, Jakus J, Harris CM, Ensley JF, Robbins KC, Yeudall WA. Altered expression and activity of G1/S cyclins and cyclin-dependent kinases characterize squamous cell carcinomas of the head and neck. Int J Cancer 1997;73:551-555   DOI   ScienceOn
24 Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 1994;201:589-595   DOI   ScienceOn
25 Raju U, Ariga H, Koto M, et al. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases. Radiother Oncol 2006;80:185-191   DOI   ScienceOn